URICOSURIC COMPOSITION

Abstract: The present invention relates to a uricosuric composition comprising a quinazoline derivative of the general formula (I): wherein R¹ and R³ each is a hydrogen atom or a halogen atom or a pharmaceutically acceptable salt thereof as an active ingredient and to the use thereof for the manufacture of a drug for the treatment of gout.

Description: The present invention relates to the use of a quinazoline derivative of the following general formula (I) or of a pharmaceutically acceptable salt thereof as an active ingredient for the manufacture of a medicament for excreting uric acid from the human body as well as for the manufacture of a medicament for preventing and/or treating gout which as such, find application in the field of health care. The quinazoline derivative (I) used according to this invention is a known compound and has been demonstrated to have aldose reductase-inhibitory activity [see JP-A- 62-96 476 (1987)]. It is not known, however, that the derivative has uricosuric activity. This invention relates to the use of a quinazoline derivative of the general formula (I): wherein R¹, R² and R³ each is a hydrogen atom or a halogen atom or of a pharmaceutically acceptable salt thereof as an active ingredient for the manufacture of a medicament for excreting uric acid from the human body. Furthermore, the present invention relates to the use of a quinazoline derivative of the general formula (I) as defined above or of a pharmaceutically acceptable salt thereof as an active ingredient for the manufacture of a medicament for preventing and/or treating gout. In the above definition of quinazoline derivative (I), the halogen designated independently by R¹, R² and R³ includes chlorine, bromine, iodine and fluorine. The pharmceutically acceptable salts of quinazoline derivative (I) include salts with inorganic bases such as alkali metals (e.g. sodium and potassium) and alkaline earth metals (e.g. calcium and magnesium), ammonium salts, salts with organic basis such as organic amines (e.g. triethylamine, pyridine, picoline, ethanolamine, triethanolamine, dicyclohexylamine and N,N'-dibenzylethylenediamine) and salts with basic amino acids (e.g. arginine). The quinazoline derivative (I) and pharmaceutically acceptable salts used according to this invention have uricosuric activity and are, therefore, of value as the active ingredient of uricosuric compositions. The uricosuric composition prepared according to this invention is effective in the treatment and/or prevention of gout. The active ingredient, quinazoline derivative (I) or a pharmaceutically acceptable salt thereof, may be administered as such but is generally administered as formulated into various pharmaceutically acceptable compositions. As dosage forms useful for such compositions, there may be mentioned injections, capsules, granules, powders and tablets. Such pharmaceutical compositions are formulated by the established pharmaceutical procedures using excipients (e.g. sucrose, starch, mannit, sorbit, lactose, glucose, cellulose, talc, calcium phosphate and calcium carbonate), binding agents (e.g. cellulose, methyl cellulose, hydroxypropylmethyl cellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose and starch), disintegrators (e.g. starch, carboxymethyl cellulose, hydroxypropyl starch, sodium bicarbonate, calcium phosphate and calcium citrate), lubricants (e.g. magnesium stearate, talc and sodium laurylsulfate, flavoring agents (e.g. citric acid, menthol, glycine and orange powders), preservatives (e.g. sodium benzoate, sodium bisulfite, methylparaben and propylparaben), stabilizers (e.g. citric acid, sodium citrate and acetic acid), suspending agents (e.g. methyl cellulose, polyvinylpyrrolidone and aluminum stearate, dispersing agents (e.g. hydroxypropylmethyl cellulose), solvents (e.g. water), base wax (e.g. cacao butter, white petrolatum and polyethylene glycol. While the dosage of the uricosuric composition prepared according to this invention is dependent on the patient's age and body weight, clinical condition and method of administration, a daily dose of generally 10 to 1800 mg as quinazoline derivative (I) or a pharmaceutically acceptable salt thereof, or preferably 30 to 1200 mg on the same basis, is administered orally or parenterally in a single dose to 3 divided doses. The following test examples are intended to illustrate the excellent uricosuric action and low toxicity of the quinazoline derivative (I) or a pharmaceutically acceptable salt thereof. Test compound (1) 2-[7-Chloro-3-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxoquinazolin-1-yl]acetic acid (hereinafter referred to briefly as compound A). (2) 2-[7-Fluoro-3-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxoquinazolin-1-yl]acetic acid (hereinafter referred to briefly as compound B). (a) Uricosuric action: Method Compound A, in a single dose of 600 mg (two capsules according to the example (1) given hereinafter), was administered orally to six humans (healthy male adult volunteers) and the serum uric acid level was determined for 48 hours after administration. The results are shown in the following table. (b) The effect of Compound B on uric acid excretion in female rats Method Female SD rats (6 weeks old) were fasted for 18 hours and submitted to the test (3 animals per group). Compound B was suspended in 0.5% methylcellulose solution and the suspension was orally administered in a dosing volume of 5 ml/kg. At the same time, the animals were orally loaded with 20 ml/kg of physiological saline. Urine samples were collected up to 6 hours after drug administration. The uric acid in each urine sample was assayed by HPLC. Results Dose (mg/kg, p.o.) Number of groups Excretion of uric acid (mg/kg) 0 3 3.07 ± 0.44 10 3 3.36 ± 0.14 100 3 4.02 ± 0.18 320 3 4.88 ± 0.24 Period for collection of urine: 0-6 h Mean ± S.E. (c) Acute toxicity: Male SD rats (5 animals per group) were orally dosed with a suspension of the test compound in 0.5% methylcellulose solution and observed for 14 days after oral administration. Results LD₅₀ Compound A 4250 mg/kg Compound B 2144 mg/kg Example 1 A powder of the following formula is encapsulated to provide a capsule. Formula Compound A 300 mg Low-substituted hydroxypropylcellulose 30 mg Polyoxyl 40 Stearate 3 mg Hydroxypropylcellulose 3 mg Example 2 The ingredients in the following formula are blended and granulated into granules in a conventional manner. Formula for granules Compound A 30.0% (by weight) Lactose 69.4% Polyoxyl 40 Stearate 0.1% Hydroxypropylcellulose 0.5% Example 3 The ingredients in the following formula are blended and powdered into powders in a conventional manner. Formula for powders Compound A 30.0% (by weight) Lactose 69.4% Polyoxyl 40 Stearate 0.1% Hydroxypropylcellulose 0.5% Example 4 The ingredients in the following formula are blended and compressed into tablets in a conventional manner. Formula for a tablet Compound A 300 (mg) Lactose 100.8 Cross-Linked sodium carboxymethylcellulose 9 Hydroxypropylcellulose 3 Polyoxyl 40 Stearate 3 Magnesium Stearate 4.2 420 mg /tablet Thus obtained tablets are, when desired, coated with film-coating or enteric coating. Example 5 Compound A (5 g) and sodium hydroxide (450 mg) are dissolved in distilled water for injection to give injectable solution (10 ℓ) and the injectable solution is divided to 100 ampoules in a conventional manner. The above-mentioned compositions (capsule, granule, powder, tablet, injection) are also prepared by using compound B instead of compound A.

Claims: Use of a quinazoline derivative of the general formula: wherein R¹, R² and R³ each is a hydrogen atom or a halogen atom or of a pharmaceutically acceptable salt thereof for the manufacture of a medicament for excreting uric acid from the human body. Use of a quinazoline derivative of the general formula: wherein R¹, R² and R³ each is a hydrogen atom or a halogen atom or of a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing and/or treating gout.

Inventors: KANAMARU, MITSUTAKA, NAKASHIMA, MITSUYOSHI, SUGIYAMA, AKIRA, TERAKAWA, MASATO
Applicants: FUJISAWA PHARMACEUTICAL CO., LTD.
Application year: 1988
Main classification: A61K31
IPC codes: A61K31